Brutalist Biotech

• Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor in new indication (19h)
• BrightGene tops Novo drug in diabetes ahead of Zepbound showdown (20h)
• Corxel, Sciwind post GLP-1 data as China's obesity push gathers pace (20h)
• Leap expands layoffs to cover 75% of employees, scraps only clinical trial to save cash (21h)
• Compass points to psychedelic therapy's phase 3 depression win, but investors unimpressed (22h)
• Exelixis' blockbuster hopeful beats Bayer drug in pivotal cancer trial, sending stock soaring (22h)
• Otsuka pens $670M pact to point Harbour’s preclinical T-cell engager to autoimmune disease (23h)
• Novo's injectable amycretin yet to hit weight loss plateau, suggesting Zepbound-beating potential (1d)
• Vertex’s remaining islet cell therapy reduces dangerously low blood sugar levels in phase 1/2 test (1d)
• Abbott lines up insulin pump collabs for its upcoming glucose-ketone sensor (3d)

• Relentless innovation: Bold exploration in advancing therapeutic options for every patient, every discovery (14h)
• Top drug official at FDA reportedly set to exit next month (15h)
• Cidara stock soars as antiviral drug succeeds in flu study (17h)
• Novo abruptly ends obesity drug deal with Hims (17h)
• Compass’ big psychedelic study doesn’t impress investors (18h)
• Illumina to buy SomaLogic in deal worth up to $425M (18h)
• [Podcast] Trial Trailblazers: Behind clinical breakthroughs (21h)
• The rise of GLP-1 drugs: Transforming weight loss treatment (1d)
• Prothena to lay off majority of staff; Zealand shares obesity drug data (3d)
• A longer ‘winter’: Public funding slowdown heightens pressure on biotech startups (3d)

• Politics collide with science ahead of new ACIP meeting (13h)
• Amgen plans more gradual MariTide dosing in Phase 3 (13h)
• FDA approves AstraZeneca, Daiichi Sankyo's Datroway in EGFR-mutated lung cancer (13h)
• Roche plans to pit next-gen hemophilia A antibody against Hemlibra in Phase 3 (14h)
• Supreme Court asks DOJ to weigh in on Hikma ‘skinny label’ fight (17h)
• Exelixis' positive Phase 3 colorectal cancer data boost stock (18h)
• Novo Nordisk ends partnership with Hims over compounded drugs (18h)
• Formation Bio’s up to €545M licensing deal with Sanofi; Otsuka, Harbour BioMed team up (18h)
• Cidara's preventive influenza biologic is effective in Phase 2b trial (18h)
• Acting CDER chief to depart FDA in July (19h)

• Washington's Policy Shifts Are Driving Capital Away From Life-Saving Research (5h)
• FDA Conditional Pathway Not Necessary, Rare Disease Experts Say, While Applauding Intent (5h)
• Acting CDER Head Becomes Latest in String of FDA Leaders to Leave Agency (18h)
• Lilly Takes Victory Lap on Oral Weight Loss Drug as Analysts Spot Safety Crack (18h)
• Exelixis Beats Bayer in Colorectal Cancer as Zanzalintinib Delivers ‘First Pivotal Success’ (19h)
• Novo Leans on CagriSema’s Safety as Amycretin Moves Forward to Phase III (20h)
• Compass Plots Path to FDA With ‘Meaningful’ Phase III Data for Psilocybin Drug in Depression (20h)
• Prothena Downsizes by 63% in Aftermath of AL Amyloidosis Failure (21h)
• Vertex’s Cell Therapy Could Be ‘Functional Cure’ for Diabetes, but Market Prospects Uncertain (21h)
• IRA Leaves Orphan Drugs Stranded Even as Regulators Promise Progress (1d)

Bio IT World

• Pangaea Data, Alexion Collaboration, Dell to Develop Supercomputer, More (4h)
• Nanoneedle Patch Enables Non-Invasive Tissue Sampling Offering Spatiotemporal Insights (5d)
• Black Swan Initiative: Multi-Pronged Research Strategy Targets Multiple Myeloma Cure (6d)
• Pistoia Alliance’s FAIR Maturity Assessment Tool (1w)
• Veteran ‘Lord of the Flies’ Takes a Crack at Addiction (2w)
• NVIDIA, Novo Nordisk Collaborate to Bring AI Agents to Drug Discovery (2w)
• A Farewell to Stan Gloss: Leading with Generosity and Other Words of Wisdom (2w)
• MIT Researchers Unveil Boltz-2: AI Model Predicts Protein Structure, Binding Affinity in Seconds (2w)
• Smart Bandage Merges Sensor Technology, Microfluidics, and AI (3w)
• A Practical Precision Medicine Approach to Complex Chronic Diseases (3w)

• Why this health tech investor thinks AI could bring the ‘learning health system’ to life (1h)
• ‘Too many, too soon’? Debunking a common fear about kids’ vaccines (1h)
• Balkanization of vaccine policy raises concerns about vaccine uptake, insurance coverage, experts warn (1h)
• A grim milestone: U.S. is on the cusp of losing its official measles elimination status (1h)
• From boom to bitcoin: A device maker’s surprising pivot amid a Medicare crackdown (1h)
• Cassidy calls to delay meeting of CDC’s vaccine panel in challenge to RFK Jr. (9h)
• Health insurers promise to reduce barriers to care under pressure from Trump administration (12h)
• GLP-1 drug helped type 1 diabetes patients keep healthy glucose levels and lose weight (13h)
• Vertex stem cell therapy spurs insulin independence (14h)
• The Senate’s version of Trump’s tax-cut bill threatens safety-net hospitals like ours (14h)

• NVIDIA Releases Agentic AI Blueprint for Literature Review and Target Discovery (4d)
• Nabla Raises $70M Series C to Expand Agentic AI Platform for Clinical Workflows (5d)
• Axiom Bio Releases Human Liver Toxicity Dataset with 130,000 Compounds to Advance AI-based Toxicity Prediction (5d)
• Xaira Publishes Largest Public Perturb-seq Atlas to Advance Virtual Cell Modeling (6d)
• Agenus and Noetik Partner to Develop AI-Based Biomarkers Using Virtual Cell Models (6d)
• Isomorphic Labs Appoints Ben Wolf as Chief Medical Officer, Expands to U.S. Hub in Cambridge (6d)
• Ryght AI Raises $3M to Automate Clinical Trial Site Activation with Agentic AI (1w)
• AstraZeneca Signs $5.3B AI Drug Discovery Deal with CSPC for Chronic Disease Programs (1w)
• Insilico Medicine Completes Oversubscribed Series E, Bringing Total Funding to $123 Million (1w)
• Sofinnova Partners and NVIDIA Collaborate to Provide GPU Access to AI-Driven Life Sciences Startups (2w)

• Turning plastic into medicine: Closing the loop on pharma production (18h)
• Special Episode: The 2025 BIO International Convention (4d)
• Stem cell therapy: a potential cure for hearing loss? (4d)
• 10 cultured meat companies driving sustainable food in 2025 (5d)
• From undruggable to oral therapy: The rise of STAT6 degraders (6d)
• Six kidney disease companies you should know about in 2025 (6d)
• Did Novo open the Canadian market to GLP-1 generics? (1w)
• A new era in migraine treatment: Innovative drugs redefining the field (1w)
• Alex Telford on AI, drug discovery, digital twins, and the most interesting questions in biotech (2w)
• Behind the Cure51 deal: Is NVIDIA becoming biotech’s AI infrastructure? (2w)

• Brain Receptor Structure Revealed to Support Cerebellum Function Repair (7h)
• Scientific Data Crisis Holds Back CMC (12h)
• Rare Gene Mutation Delays Alzheimer’s by Damping Immune Cell Inflammatory Signaling (13h)
• Potency Assays in Cell and Gene Therapy: Strategies for Manufacturing and Regulatory Success (13h)
• Novel Molecule May Rival GLP-1 Agonists for Diabetes and Obesity Treatment (18h)
• Novel Molecule May Rival GLP-1s for Diabetes and Obesity Treatment (18h)
• Illumina to Acquire SomaLogic from Standard BioTools (18h)
• LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma (21h)
• StockWatch: CGT Stocks Fall on FDA Therapeutic Products Upheaval (1d)
• Intercellular Fluid Flow Impacts Tissue Response to Physical Forces (3d)

• Faith, Friendship and Finding Purpose After Breast Cancer (12h)
• A New Digital Platform Aims to Expand Access to Early Oncology Trials (14h)
• FDA Approves Datroway for EGFR-Mutated Advanced Lung Cancer (15h)
• Living My Best Life: A Family Beach Vacation After a Brain Tumor (16h)
• Spotlighting Pancreatic Cancer Disparities in Black Communities (17h)
• Illuccix is FDA Approved to Guide Radioligand Use in Prostate Cancer (18h)
• What Should Patients with Multiple Myeloma Know After ASCO 2025? (20h)
• Improving Distant Control in Lung Cancer With JNJ-1900 and Keytruda (1d)
• Experts Impart Notable Information and Updates for Those With Blood Cancers (1d)
• Breaking Down Clinical Trial Participation in Kidney Cancer: Is it Right for You? (2d)

Contract Pharma*

• Novo Nordisk Axes Relationship with Hims & Hers (14h)
• Celltrion Opens UK Headquarters in Uxbridge (19h)
• Why Project Management Is the Real Differentiator for CDMOs (19h)
• Cellular Origins, Johnson & Johnson Partner for CGT Robotics Manufacturing Platform (19h)
• Nutriband, Kindeva Complete Commercial Scale-up for Aversa Fentanyl (20h)
• Pharmalogic Acquires Majority Stake in Agilera Pharma (20h)
• Formation Bio Licenses Gusacitinib to Sanofi (20h)
• Harbour BioMed, Otsuka Partner to Advance Bispecific T-Cell Engagers (20h)
• Ferring Opens New Gene Therapy Manufacturing Facility (3d)
• Pharmaceutical Contract Manufacturing and Research Services - GlobeNewswire (3d)

• NHS rolls out new initiative to identify pancreatic cancer earlier (22h)
• eXmoor and Signadori Bio enter cell therapy partnership (5d)
• Teva and Fosun Pharma partner on early-stage oncology drug (6d)
• FDA approves UroGen’s Zusduri to treat recurrent bladder cancer (7d)
• EDX medical partners with spire healthcare to advance disease diagnostics (1w)
• Investigational treatment shows promise for aggressive multiple myeloma (1w)
• Levicept presents new LEVI-04 data at EULAR (2w)
• Migraine takes the spotlight at European Parliament (2w)
• Bimekizumab shows lasting efficacy at EULAR 2025 (2w)
• Argenx presents new efgartigimod data at EULAR 2025 (2w)

• More Than 50 Health Plans Commit to Simplifying Prior Authorization (9h)
• Why This Former OpenAI Exec Is Urging Health Leaders to ‘Specialize in Empathy’ (10h)
• Vertex Pharma’s Type 1 Diabetes Cell Therapy Shows Potential to Achieve Insulin Independence (14h)
• The Overlooked Global Warming Cost We Can’t Ignore (19h)
• The Medicaid Reckoning: Era of Fiscal and Policy Flux (20h)
• New Cohere Health Solution Aims to Streamline Clinical Reviews for Payers (1d)
• Precision Medicine Firm Caris Breaks Bio IPO Drought, Raising $494M for Cancer Analysis Tools (1d)
• Why Intermountain Health Is Investing In AI for Clinical Data Abstraction (1d)
• What OpenAI’s o3 Price Drop Means for the Future of AI in Healthcare? (1d)
• The MFN Executive Order: A Global Reset for U.S. Pharma (1d)

• Veolia opens PFAS removal plant in Delaware (13h)
• Crystals defy their symmetry to discern chiral light (15h)
• Researchers turn plastic into paracetamol (17h)
• How air pollution can cause kidney disease (19h)
• Draig Therapeutics flies out of stealth to treat depression (3d)
• Machine learning helps improve accuracy and efficiency of small-molecule calculations (3d)
• Chairs of 36 US chemistry departments call to restore funding (4d)
• Executives, investors stick to basics at BIO 2025 (4d)
• Podcast: Can altering ocean chemistry fight climate change? (4d)
• Acetic acid breaks down carbon fiber–reinforced polymers (5d)

The Pharma Letter*

• Lilly’s oral GLP-1 shows no liver safety issues in Phase III diabetes trial (16h)
• Medicus Pharma appoints COO; updates on SKNJCT-003 (16h)
• European approval for argenx expands autoimmune footprint (16h)
• Despite topline trial success, Compass going in wrong direction (17h)
• Otsuka in-licenses Harbour BioMed’s HBM7020 (18h)
• Industry anger at FDA oustings (18h)
• Ono to sell Vertex’s povetacicept in Japan (19h)
• Positive Phase III Study of Winrevair in PAH (19h)
• New data demonstrates robust efficacy of Vyepti in severe migraine (20h)
• EFPIA underlines its role in disclosure of pharma payments (20h)

• Walking Through the First 3 Physician Visits for Patients with mHSPC (14h)
• Zanzalintinib/Atezolizumab Improves CRC Survival, Expands TKI's Role in Solid Tumors (15h)
• FDA Grants Accelerated Approval to Dato-DXd in Previously Treated EGFR+ NSCLC (15h)
• Pirtobrutinib Outperforms Standard Options in Relapsed/Refractory CLL/SLL (15h)
• Dr Muvner on Targeted Therapies in Prostate Cancer (16h)
• Hochhaus on ASC4START and Asciminib’s Superior Tolerability in CML-CP (17h)
• Dr Abramson on ASCO 2025 DLBCL Updates: What's New? (18h)
• FDA Clears IND for Phase 1 Study of Lonitoclax in Relapsed/Refractory AML (19h)
• Mismatched Unrelated Donors & PTCy: Better HSCT Outcomes, Expanded Access (19h)
• Navigating the Treatment Landscape in Non–Clear Cell Renal Cell Carcinoma (20h)

• Analyst: Novo Nordisk shows “decisiveness” by dropping partner after dispute over generic drugs (1h)
• Him & Hers boss hits back after Novo's decision to end partnership (1h)
• Lundbeck drug granted special status in Europe and the US (2h)
• CHMP recommends 13 new medicines for approval – and makes use of rare exception rule (3h)
• Novo Nordisk ends collaboration with US partner after two months (20h)
• GN gains market share among US veterans in May (20h)
• Trump's "most favored nation” policy puts pressure on EU pharma industry (21h)
• Eli Lilly expects results from obesity candidate in the third quarter (23h)
• Novo Nordisk presents detailed data on weight loss candidate cagrisema (1d)
• Novo Nordisk presents data on higher dose of Wegovy (1d)

• Hexanitrogen (12h)
• Stir Bars Can't Be Ignored (5d)
• AI Effects on Drug Patents (1w)
• Mirror Morphine (2w)
• Vaccine Advice, Vandalized (2w)
• Novo Nordisk's Canadian Mistake (2w)
• The Bethesda Declaration (2w)
• Taurine and Aging: Is There Anything to It? (2w)
• Cleaning Up the Medical Literature (3w)
• Not One of Your Easy Crystals (3w)

• Senator says ACIP next meeting should be postponed (55m)
• NHS records to be harnessed in pancreatic cancer screening (20h)
• EU kicks off review of GSK's linerixibat in PBC (21h)
• Roche's Hemlibra follow-up set for phase 3 in haemophilia A (22h)
• ADA: Lilly makes its case for oral GLP-1 orforglipron (23h)
• ADA: Novo continues effort to rehabilitate CagriSema (1d)
• Madrigal closes on EU approval of first MASH treatment (3d)
• Grail plans FDA filing for cancer blood test after new trial (3d)
• Dupixent is first FDA-approved drug for rare skin disease (4d)
• FDA blocks trials that send US cells to 'hostile' countries (4d)

• The significance of mAbs in drug discovery and development (1h)
• eBook: The significance of mAbs in drug discovery and development (1h)
• Study supports monovalent antibody in neuropsychiatric disease (21h)
• New discovery could advance drugs for diabetes and obesity (23h)
• New DDW Highlights podcast: 22 June 2025 (1d)
• What international reference pricing could mean for US drug costs (1d)
• DDW Highlights: 22 June 2025 (1d)
• Last chance to register: How is AI innovating in drug discovery? (1d)
• This week in drug discovery (16-20 June) (3d)
• All-in-one vaccine development backed by $12.4m funding (3d)

Google News Biotech

• Gene Therapy Market Top Companies Study -Krystal Biotech, Inc., - openPR.com (29m)
• Citizens JMP reiterates Sana Biotechnology stock rating on diabetes data - Investing.com (41m)
• Danish BioTech startup Cellugy secures €8.1 million to eradicate microplastics in personal care products - EU-Startups (58m)
• Nurturing biotech company creation - VC Magazin (1h)
• Sonrai and Plectonic Biotech partner to advance cancer immunotherapies - European Biotechnology Magazine (1h)
• Danish Green Biotech Firm Cellugy Secures $9.25 M to Replace Microplastics in Cosmetics - Cosmetics & Toiletries (1h)
• Taiwanese Biotech Delegation Heads to Phoenix, Forging New International Collaborations - geneonline.com (1h)
• 13 Best Biotech Stocks To Invest In Now - Insider Monkey (1h)
• Italy and Germany block central green deal legislation - European Biotechnology Magazine (1h)
• Cell Line Development Market Experiences Rapid Innovation as - openPR.com (2h)